Lindner D, Job J C, Chaussain J L
Hopital St Vincent de Paul, Paris, France.
Eur J Pediatr. 1993 May;152(5):393-6. doi: 10.1007/BF01955894.
A group of 17 endocrinologically normal short stature adolescent (9 females aged 11.8 +/- 1.5 years and 8 males aged 13.2 +/- 1.1 years) referred at a pubertal stage II-III according to Tanner with a height prediction below -2.5 SD according to Bayley and Pinneau, were treated with long-acting D-Trp6-luteinizing hormone-releasing hormone (3.75 mg i.m. monthly for 24 months) and observed for a period of 13.4 +/- 5.8 months. Pubertal progression was suppressed during the 2 years of analogue therapy, then resumed shortly after the end of treatment. Annual growth rate remained in the prepubertal range during the treatment period and did not increase with the resumption of sexual development. A reduced rate of bone maturation was observed during the 2 years of analogue treatment without clear-cut improvement of the height to bone age relationship at the end of the treatment nor after the post-treatment observation period. Thus, after approximately 3 years of study, no significant improvement of predicted adult stature was obtained. There were no side-effects, but psychological problems mainly related to the failure to increase height. Though methods for predicting adult height are not accurate, these data suggest that use of luteinizing hormone-releasing hormone analogue in endocrinologically normal short subjects entering puberty at normal age with a poor height prognosis does not offer enough possible advantages on growth to offset the possible psychological drawbacks, and cannot be considered as routine treatment in this situation.
一组17名内分泌正常的身材矮小青少年（9名女性，年龄11.8±1.5岁；8名男性，年龄13.2±1.1岁），根据坦纳分期处于青春期II - III期，按照贝利和皮诺的标准身高预测低于 -2.5标准差，接受长效D - 色氨酸6 - 促黄体生成素释放激素治疗（每月肌肉注射3.75毫克，共24个月），并观察了13.4±5.8个月。在两年的类似物治疗期间青春期进展受到抑制，治疗结束后不久恢复。治疗期间年生长速率保持在青春期前范围，且随着性发育的恢复并未增加。在两年的类似物治疗期间观察到骨成熟速率降低，治疗结束时以及治疗后观察期结束时身高与骨龄的关系均未得到明显改善。因此，经过大约3年的研究，预测的成人身高没有显著改善。没有副作用，但主要存在与身高未增加相关的心理问题。尽管预测成人身高的方法并不准确，但这些数据表明，对于年龄正常进入青春期且身高预后较差的内分泌正常的矮小个体，使用促黄体生成素释放激素类似物在生长方面没有足够的优势来抵消可能的心理缺陷，在这种情况下不能被视为常规治疗方法。
